$2.3M
3.7x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
Profitable specialty pharmacy with continued growth. Fully staffed and easily operated by an absentee owner. Direct contracts with many pharma manufacturers. All major PBM contracts in place through PSAO. Established Prior-Authorization P&P. Pharma voucher program contracts are also in place. Annual...
Why we like it
- Earnings Quality: $2.3M cash flow at 3.66x multiple suggests strong, defensible margins in a recession-resistant healthcare vertical. Specialty pharmacy cash flows are typically more predictable than retail pharmacy due to chronic patient populations requiring ongoing treatment and higher barriers to switching providers.
- Durability & Moat: Direct manufacturer contracts and established PBM relationships create significant switching costs and barriers to entry. Prior authorization processes and voucher program administration require specialized expertise that takes years to develop, protecting market position from generic competition.
- Market Tailwinds: Specialty drug spending is growing 6-8% annually as more complex biologics and targeted therapies come to market. An aging population with increasing chronic disease prevalence creates a expanding addressable market with limited new entrants due to regulatory complexity.
- Operator Advantage: Absentee owner structure with full staffing suggests systems and processes are already optimized for hands-off operation. Specialty pharmacy requires less physical footprint optimization than retail, allowing focus on payer contract negotiations and clinical program expansion.
How to improve it
- Payer Mix Optimization: Audit current payer contracts and identify opportunities to negotiate better reimbursement rates with commercial insurers. Specialty pharmacies with strong clinical outcomes data can command 2-5% higher reimbursement rates than market averages.
- Clinical Program Expansion: Launch additional patient support services like medication therapy management, injection training, and adherence monitoring. These programs typically generate $200-500 per patient annually in additional revenue while improving outcomes and retention.
- Geographic Expansion: Leverage existing manufacturer relationships and PSAO network to expand into adjacent Illinois markets or neighboring states. Specialty pharmacy licenses can often be extended geographically with existing infrastructure and contracts.
- Technology Integration: Implement advanced pharmacy management systems for inventory optimization and automated prior authorization processing. Technology upgrades typically reduce labor costs 15-25% while improving fill times and patient satisfaction.
- Acquisition Strategy: Use established payer relationships and operational systems as platform for acquiring smaller specialty pharmacies or converting traditional pharmacies to specialty focus. Consolidation opportunities exist in fragmented regional markets.
Diligence notes
- Payer Concentration Risk: Verify revenue concentration across PBM contracts and government programs. Single payer representing more than 25% of volume creates reimbursement rate negotiation risk and potential cash flow volatility during contract renewals.
- Regulatory Compliance: Conduct thorough review of DEA, state pharmacy board, and URAC accreditation status. Specialty pharmacies face heightened regulatory scrutiny, and compliance violations can result in contract termination and significant fines.
- Inventory Management: Analyze inventory turnover and dead stock levels for high-cost specialty medications. Poor inventory management in specialty pharmacy can quickly erode margins due to drug expiration and storage costs.
- Key Personnel Dependencies: Assess pharmacist licensing, clinical staff expertise, and management depth. Specialty pharmacy operations require specialized knowledge, and key person risk is elevated compared to traditional retail pharmacy operations.